Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ironwood Pharmaceuticals Long-Term Investments 2010-2024 | IRWD

Ironwood Pharmaceuticals long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
  
Ironwood Pharmaceuticals Annual Long-Term Investments
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Ironwood Pharmaceuticals Quarterly Long-Term Investments
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.744B $0.443B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $78.616B 30.25
Takeda Pharmaceutical (TAK) Japan $44.101B 9.18
Merck (MKKGY) Germany $21.176B 23.11
Astellas Pharma (ALPMY) Japan $20.449B 18.83
Sandoz Group AG (SDZNY) Switzerland $19.727B 0.00
United Therapeutics (UTHR) United States $17.973B 17.68
Summit Therapeutics (SMMT) United States $15.560B 0.00
Neurocrine Biosciences (NBIX) United States $12.553B 33.24
Shionogi (SGIOY) Japan $12.508B 11.98
Catalent (CTLT) United States $10.876B 0.00
Madrigal Pharmaceuticals (MDGL) United States $7.739B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.354B 7.04
Orion OYJ (ORINY) Finland $6.848B 19.25
Ionis Pharmaceuticals (IONS) United States $6.073B 0.00
Corcept Therapeutics (CORT) United States $5.689B 43.10
Crinetics Pharmaceuticals (CRNX) United States $4.787B 0.00
PTC Therapeutics (PTCT) United States $3.305B 0.00
Dyne Therapeutics (DYN) United States $2.939B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.773B 12.57
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.665B 15.38
Arrowhead Pharmaceuticals (ARWR) United States $2.659B 0.00
Soleno Therapeutics (SLNO) United States $2.462B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.038B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.948B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.829B 0.00
Harrow (HROW) United States $1.771B 0.00
Ocular Therapeutix (OCUL) United States $1.681B 0.00
Xencor (XNCR) United States $1.622B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.589B 0.00
ARS Pharmaceuticals (SPRY) United States $1.565B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.513B 0.00
Ardelyx (ARDX) United States $1.511B 0.00
Evotec AG (EVO) Germany $1.506B 0.00
Indivior (INDV) United States $1.492B 6.08
Enliven Therapeutics (ELVN) United States $1.370B 0.00
Guardian Pharmacy Services (GRDN) United States $1.304B 0.00
Cassava Sciences (SAVA) United States $1.216B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.193B 0.00
Collegium Pharmaceutical (COLL) United States $1.118B 6.11
Bioventus (BVS) United States $0.910B 28.82
Relay Therapeutics (RLAY) United States $0.822B 0.00
Cronos Group (CRON) Canada $0.788B 0.00
USANA Health Sciences (USNA) United States $0.772B 14.32
Tourmaline Bio (TRML) United States $0.709B 0.00
Savara (SVRA) United States $0.662B 0.00
Korro Bio (KRRO) United States $0.643B 0.00
Exscientia (EXAI) United Kingdom $0.638B 0.00
Larimar Therapeutics (LRMR) United States $0.582B 0.00
ProKidney (PROK) United States $0.559B 0.00
Siga Technologies (SIGA) United States $0.545B 6.36
Verve Therapeutics (VERV) United States $0.538B 0.00
OmniAb (OABI) United States $0.535B 0.00
Elite Pharmaceuticals (ELTP) United States $0.534B 49.99
Silence Therapeutics (SLN) United Kingdom $0.533B 0.00
Altimmune (ALT) United States $0.530B 0.00
Xeris Biopharma Holdings (XERS) United States $0.501B 0.00
KalVista Pharmaceuticals (KALV) United States $0.483B 0.00
Zevra Therapeutics (ZVRA) United States $0.464B 0.00
Aquestive Therapeutics (AQST) United States $0.463B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.445B 0.00
Organogenesis (ORGO) United States $0.432B 0.00
4D Molecular Therapeutics (FDMT) United States $0.430B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.428B 0.00
Esperion Therapeutics (ESPR) United States $0.414B 0.00
Akebia Therapeutics (AKBA) United States $0.392B 0.00
Sage Therapeutics (SAGE) United States $0.387B 0.00
Avita Medical (RCEL) United States $0.322B 0.00
Aldeyra Therapeutics (ALDX) United States $0.317B 0.00
Lyell Immunopharma (LYEL) United States $0.312B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.272B 110.29
Heron Therapeutics (HRTX) United States $0.268B 0.00
Acrivon Therapeutics (ACRV) United States $0.263B 0.00
Lexeo Therapeutics (LXEO) United States $0.261B 0.00
Nature's Sunshine Products (NATR) United States $0.257B 15.23
Nektar Therapeutics (NKTR) United States $0.252B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.240B 0.00
Pyxis Oncology (PYXS) United States $0.234B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.223B 0.00
Profound Medical (PROF) Canada $0.221B 0.00
Nanobiotix S.A (NBTX) France $0.203B 0.00
MediWound (MDWD) Israel $0.181B 0.00
Innate Pharma SA (IPHYF) France $0.180B 0.00
Galectin Therapeutics (GALT) United States $0.177B 0.00
Aclaris Therapeutics (ACRS) United States $0.175B 0.00
Achieve Life Sciences (ACHV) Canada $0.172B 0.00
Cardiol Therapeutics (CRDL) Canada $0.165B 0.00
Context Therapeutics (CNTX) United States $0.157B 0.00
Incannex Healthcare (IXHL) Australia $0.154B 0.00
CytoDyn (CYDY) United States $0.152B 0.00
VAXART, INC (VXRT) United States $0.128B 0.00
Century Therapeutics (IPSC) United States $0.124B 0.00
Telomir Pharmaceuticals (TELO) United States $0.124B 0.00
Journey Medical (DERM) United States $0.118B 0.00
OptiNose (OPTN) United States $0.116B 0.00
Fractyl Health (GUTS) United States $0.116B 0.00
AlloVir (ALVR) United States $0.113B 0.00
Karyopharm Therapeutics (KPTI) United States $0.111B 0.00
Relmada Therapeutics (RLMD) United States $0.098B 0.00
Regulus Therapeutics (RGLS) United States $0.097B 0.00
Assertio Holdings (ASRT) United States $0.096B 16.83
PMV Pharmaceuticals (PMVP) United States $0.092B 0.00
Arch Biopartners (ACHFF) Canada $0.091B 0.00
CASI Pharmaceuticals (CASI) China $0.087B 0.00
ElectroCore (ECOR) United States $0.082B 0.00
ESSA Pharma (EPIX) Canada $0.079B 0.00
Metagenomi (MGX) United States $0.076B 0.00
Swiftmerge Acquisition (IVCP) United States $0.076B 368.67
Prelude Therapeutics (PRLD) United States $0.070B 0.00
Vivani Medical (VANI) United States $0.070B 0.00
Citius Pharmaceuticals (CTXR) United States $0.069B 0.00
Inotiv (NOTV) United States $0.068B 0.00
Nutriband (NTRB) United States $0.062B 0.00
Champions Oncology (CSBR) United States $0.059B 0.00
Mural Oncology (MURA) Ireland $0.058B 0.00
Gain Therapeutics (GANX) United States $0.057B 0.00
Qilian Holding Group (BGM) China $0.055B 0.00
Unicycive Therapeutics (UNCY) United States $0.054B 0.00
Protara Therapeutics (TARA) United States $0.052B 0.00
SCYNEXIS (SCYX) United States $0.050B 0.00
Rafael Holdings (RFL) United States $0.047B 0.00
VYNE Therapeutics (VYNE) United States $0.047B 0.00
Carisma Therapeutics (CARM) United States $0.043B 0.00
DURECT (DRRX) United States $0.042B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.038B 0.00
BioLineRx (BLRX) Israel $0.036B 0.00
Surrozen (SRZN) United States $0.033B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.032B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.031B 0.00
FibroGen (FGEN) United States $0.031B 0.00
Oruka Therapeutics (ORKA) United States $0.031B 0.00
Lipocine (LPCN) United States $0.030B 0.00
Iterum Therapeutics (ITRM) Ireland $0.030B 0.00
Natural Alternatives (NAII) United States $0.028B 0.00
ProPhase Labs (PRPH) United States $0.027B 0.00
Enlivex Therapeutics (ENLV) Israel $0.027B 0.00
GlycoMimetics (GLYC) United States $0.027B 0.00
Tempest Therapeutics (TPST) United States $0.027B 0.00
BioVie (BIVI) United States $0.025B 0.00
Inhibikase Therapeutics (IKT) United States $0.021B 0.00
MEI Pharma (MEIP) United States $0.020B 0.70
Marinus Pharmaceuticals (MRNS) United States $0.020B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.019B 0.00
TherapeuticsMD (TXMD) United States $0.018B 0.00
Lyra Therapeutics (LYRA) United States $0.017B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.017B 0.00
PolyPid (PYPD) Israel $0.016B 0.00
Minerva Neurosciences (NERV) United States $0.016B 0.00
Cosmos Health (COSM) United States $0.016B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.016B 0.00
Talphera (TLPH) United States $0.015B 0.00
Mannatech (MTEX) United States $0.015B 0.00
Scienture Holdings (SCNX) United States $0.014B 0.00
NRx Pharmaceuticals (NRXP) United States $0.014B 0.00
Nuvilex (PMCB) United States $0.014B 0.00
Vivos Therapeutics (VVOS) United States $0.014B 0.00
Avalo Therapeutics (AVTX) United States $0.013B 0.00
Indaptus Therapeutics (INDP) United States $0.012B 0.00
Addex Therapeutics (ADXN) Switzerland $0.011B 0.00
CERo Therapeutics Holdings (CERO) United States $0.011B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.011B 0.00
Dominari Holdings (DOMH) United States $0.011B 0.00
Redhill Biopharma (RDHL) Israel $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
Traws Pharma (TRAW) United States $0.009B 0.00
Conduit Pharmaceuticals (CDT) United States $0.009B 0.00
Jaguar Animal Health (JAGX) United States $0.009B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Plus Therapeutics (PSTV) United States $0.008B 0.00
Viracta Therapeutics (VIRX) United States $0.007B 0.00
Klotho Neurosciences (KLTO) United States $0.007B 0.00
Aptorum Group (APM) United Kingdom $0.007B 0.00
Biomerica (BMRA) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Mangoceuticals (MGRX) United States $0.005B 0.00
SHINECO (SISI) China $0.005B 0.00
Oncternal Therapeutics (ONCT) United States $0.004B 0.00
Ainos (AIMD) United States $0.004B 0.00
Heatwurx (PCSA) United States $0.004B 0.00
TNF Pharmaceuticals (TNFA) United States $0.004B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Avenue Therapeutics (ATXI) United States $0.003B 0.09
Alaunos Therapeutics (TCRT) United States $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
Phio Pharmaceuticals (PHIO) United States $0.003B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
Molecular Templates (MTEM) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Bio-Path Holdings (BPTH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.002B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.002B 0.00
Aditxt (ADTX) United States $0.002B 0.00
Qualigen Therapeutics (QLGN) United States $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.001B 0.00
PainReform (PRFX) Israel $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 3.21
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 44.55